Speaker Profile
Ph.D., CEO, L7 Informatics
Biography
Vasu Rangadass, Ph.D., is the CEO of L7 Informatics, a company that delivers software and services enabling DATA+INTELLIGENCE for science and health. Since joining L7, Dr. Rangadass has led the further development of the Enterprise Science Platform (L7ESP), a cutting-edge scientific process and data management solution that empowers life science and healthcare organizations to connect people, processes, and systems, accelerating discoveries and advancing precision healthcare.Prior to L7 Informatics, Dr. Rangadass served as Chief Strategy Officer at NantHealth, following its acquisition of Net.Orange, the company he founded. Net.Orange provided an enterprise-wide platform, the Clinical Operating System (cOS), designed to simplify and optimize care delivery processes within health systems. With a rich background in digital health and a passion for transforming healthcare through innovative technology, Dr. Rangadass continues to lead initiatives that drive impactful change in the industry.
Talk
Orchestration Platforms: The Key for Enterprise Knowledge Generation and Intelligence
Explore how orchestration platforms serve as the foundation for AI-ready data contextualization and real-time intelligence in life sciences. L7's CEO, Vasu Rangadass, Ph.D, and team highlights the transformative potential of digital orchestration platforms in creating departmental & Enterprise knowledge graphs and driving Artificial intelligence models.
AI and Data Sciences Showcase:
L7 Informatics
L7 Informatics, Inc. is a leading provider of integrated scientific data and analytics solutions. The company offers a comprehensive platform that enables seamless data integration, advanced analytics, and collaborative workflows, empowering scientists and researchers to accelerate discoveries, improve operational efficiencies, and drive innovation.
Session Abstract – PMWC 2025 Silicon Valley
The PMWC 2025 AI Company Showcase will provide a 15-30 minute time slot for selected AI companies to present their latest technologies to an audience of leading investors, potential clients, and partners. We will hear from companies building technologies that expedite the pre-clinical and clinical drug discovery and development process, accelerate patient diagnosis and treatment, or develop scalable systems framework to make AI and deep/machine learning a reality.
